Zobrazeno 1 - 10
of 115
pro vyhledávání: '"Ilya Tsimafeyeu"'
Autor:
Ilya Tsimafeyeu, Maria Volkova, Galina Alekseeva, Maria Berkut, Alexander Nosov, Igor Myslevtsev, Andrey Andrianov, Andrey Semenov, Pavel Borisov, Ruslan Zukov, Vadim Goutnik, Sergey Savchuk, Natalia Dengina, Timur Mitin
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-7 (2021)
Abstract Background To our knowledge, there is no clinical data pertaining to COVID-19 outcomes and safety of COVID-19 vaccination in Russian patients with genitourinary (GU) malignancies. Aim of our analysis was to describe the characteristics of th
Externí odkaz:
https://doaj.org/article/327450f2529e49c6979c079d0e90fb21
Autor:
Ilya Tsimafeyeu, Oxana Shatkovskaya, Sergei Krasny, Nurzhan Nurgaliev, Ilya Varlamov, Vladislav Petkau, Sufia Safina, Ruslan Zukov, Mikhail Mazhbich, Galina Statsenko, Sergey Varlamov, Olga Novikova, Igor Zaitsev, Pavel Moiseyev, Alexander Rolevich, Alesya Evmenenko, Irina Popova, Dilyara Kaidarova, Liubov Vladimirova
Publikováno v:
Cancer Reports, Vol 4, Iss 3, Pp n/a-n/a (2021)
Abstract Background Real‐world data describing outcomes of treatment among metastatic renal cell carcinoma (mRCC) patients are limited and heterogeneous. Aim RENSUR3 registry study assessed real‐world data on the use of therapies in mRCC and over
Externí odkaz:
https://doaj.org/article/2f3fdafb12794e8ebeff801e78ecee6e
Autor:
Ilya Tsimafeyeu, Fedor Moiseenko, Sergei Orlov, Elena Filippova, Alexander Belonogov, Aleksey Nebesnykh, Amir Khalimov, Elena Karabina, Valentina Shikina, Ahmed Abdelgafur, Galina Statsenko, Irina Titova, Dmitry Isaichikov, Galina Makarnyaeva, Aleksey Mordovskiy, Oksana Barkovskaya, Aleksey Smirnov, Marina Gikalo, Nikita Savelov, Dmitry Kosov, Evgeny Imyanitov, Irina Demidova, Sergei Tjulandin
Publikováno v:
Journal of Global Oncology, Vol 5, Pp 1-7 (2019)
PURPOSE: The overall survival (OS) results in patients with ALK-positive metastatic non–small-cell lung cancer (NSCLC) have rarely been reported. The aim of this prospective-retrospective cohort study was to obtain real-world data on the use of cri
Externí odkaz:
https://doaj.org/article/2ab879efa3684da48f55386215f32008
Autor:
Natalia Dengina, Timur Mitin, Sergey Gamayunov, Sufia Safina, Yuliya Kreinina, Ilya Tsimafeyeu
Publikováno v:
ESMO Open, Vol 4, Iss 5 (2019)
Background Tyrosine kinase inhibitors (TKIs) and checkpoint inhibitors have been established as effective treatment for metastatic renal cell carcinoma (mRCC), but only a minority of patients achieve complete response. Additional strategies are neces
Externí odkaz:
https://doaj.org/article/541676ecaac74a43be18b600eb3890a0
Autor:
Ilya Tsimafeyeu, Galina Statsenko, Liubov Vladimirova, Natalia Besova, Grigory Raskin, Ivan Rykov, Anastasia Mochalova, Igor Utyashev, Svetlana Gorbacheva, Vasily Kazey, Evgenia Gavrilova, Nadezhda Dragun, Vladimir Moiseyenko, Sergei Tjulandin, Elena Artamonova
Publikováno v:
Investigational New Drugs. 41:324-332
Purpose Alofanib is a small-molecule allosteric extracellular FGFR2 inhibitor. We report safety and preliminary efficacy from the first-in-human phase 1b study of alofanib in heavily pretreated patients with advanced gastric cancer. Methods The stand
Autor:
Mikhail Mazhbich, L. Yu. Vladimirova, O. Yu. Novikova, Vladislav Petkau, Galina Alekseeva, M. A. Mukhina, Ilya Tsimafeyeu, Andrey Semenov, Ruslan Zukov, Galina Statsenko, Ludmila Gurina, Irina L. Popova, I. V. Zaytsev
Publikováno v:
Onkourologiâ, Vol 17, Iss 3, Pp 102-109 (2021)
Background. Data on the overall survival (OS) of patients with metastatic bladder cancer (BCa) is rarely published.The objective of the URRU register study is to assess OS and collect information on the administration of different treatments in patie
Autor:
Maria Volkova, Pavel Borisov, Ilya Tsimafeyeu, Sergey Savchuk, Vadim Goutnik, Alexander Nosov, Andrey Semenov, Natalia Dengina, Ruslan Zukov, Igor Myslevtsev, Galina Alekseeva, Maria Berkut, Timur Mitin, Andrey Andrianov
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-7 (2021)
Journal of Hematology & Oncology
Journal of Hematology & Oncology
Background To our knowledge, there is no clinical data pertaining to COVID-19 outcomes and safety of COVID-19 vaccination in Russian patients with genitourinary (GU) malignancies. Aim of our analysis was to describe the characteristics of the COVID-1
Autor:
Ilya Tsimafeyeu
Publikováno v:
Kidney Cancer. 5:63-71
On November 23, 2015, the US Food and Drug Administration (FDA) approved nivolumab for the treatment of metastatic renal cell carcinoma (RCC), thus opening a new era of immunotherapy for this tumor. This review summarizes the 5-year experience of stu
Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma
Autor:
Ruslan Zukov, Anastasia Bondarenko, Kristina Zakurdaeva, Yulia Tishova, Ilya Tsimafeyeu, Pavel Borisov
Publikováno v:
American Journal of Clinical Oncology. 44:137-142
Background Fatigue is one of the most common adverse events of systemic therapy in patients with metastatic renal cell carcinoma (RCC). The aim of multicenter randomized phase 2 study was to determine the efficacy and safety of testosterone in patien
Autor:
Saida Ashuba, Dmitry Khochenkov, Vsevolod Matveev, Yulia Khochenkova, Anna Sergeevna Olshanskaya, Elyso Solomko, Maria Volkova, Ilya Tsimafeyeu
Publikováno v:
Central European Journal of Urology
Introduction The aim of our study was to investigate expression levels and the prognostic value of multiple growth factors and their receptors in the primary tumor cells of renal cell carcinoma (RCC). Material and methods Expression of vascular endot